RO7790121 Placebo, RO7790121
CS45570
Phase 2 small_molecule active
Quick answer
RO7790121 Placebo, RO7790121 for Moderate to Severe Atopic Dermatitis (AD) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Moderate to Severe Atopic Dermatitis (AD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active